REMARKS

The Examiner contends that the information disclosure statement filed October 24, 2002 fails to comply with 37 C.F.R. § 1.98(a)(2). In order to be fully responsive, Applicants have enclosed herewith a courtesy copy of the Information Disclosure Statement as filed together with copies of the listed foreign patents and non-patent literature. It is requested that the listed references be included in the "References Cited" portion of any patent issuing from this application.

Claims 69 and 85 have been amended to more particularly point out and distinctly claim the subject matter which the Applicants regard as their invention. Specifically, they have been amended to include the limitation recited in claims 76 and 96, respectively and thus claims 76 and 96 have been cancelled without prejudice. Since dependent claims 76 and 96 were not rejected or objected to by the Examiner, the Applicants contend that including the limitation recited in these claims renders claims 69 and 85 allowable and free of the art.

Claims 69 and 85 are fully supported by the instant specification. Support for the recitation in amended claims 69 and 85 of the 10% reduction in comparison to a subcutaneous dosage can be found, for example, in claims 6 and 41 as originally filed. Accordingly, no new matter has been added.

After entry of this amendment claims 69-75, 77-95 and 97-104 will be pending in the application.

DOUBLE PATENTING REJECTION

Claims 69-104 stand provisionally rejected under the judicially created doctrine of obviousness-type double patenting as allegedly being unpatentable over claims 1-6, 12-25, 31-47, 53-56, and 62-63 of copending application 09/893,746. As this is a <u>provisional</u>, obviousness-type double-patenting rejection, Applicants will not address the rejection on its merits at this time.

CONCLUSION

In light of the above amendments and remarks, the Applicants respectfully request that the Examiner enter the amendments and consider the remarks made herein. Withdrawal

of all rejections, and an early allowance is earnestly sought. The Examiner is invited to call the undersigned attorney if a telephone call could help resolve any remaining items.

Respectfully submitted,

Date January 18, 2005

Laura A. Coruzzo 30,742

aura A. Coruzzi

JONES DAY

222 East 41st Street

New York, N.Y. 10017-6702

(212) 790-9090

OCT 23 2002

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no second are reported to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of 2

Complete if Known					
Application Number	10/028,989				
Filing Date	December 28, 2001				
First Named Inventor	PETTIS et al. Of 7				
Group Art Unit	3763 Tra 2 4 2000				
Examiner Name	Not Yet Assigned O/ OG				
Attorney Docket Number	7767-177409 CFAD.				

				U.S. PATENT DOCUM	MENTS	
Examiner Initials *	Cite No.1	U.S. Patent Document Kind Code ² (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevar Passages or Relevant Figures Appear
(Sa). AA 2,619,962		Rosenthal	12/02/1952			
1	AB	3,814,097		Ganderton et al.	06/04/1974	
	AC	3,964,482		Gerstel et al.	06/22/1976	
	AD	4,270,537		Romaine	06/02/1981	
	AE	4,592,753		Panoz	06/03/1986	
	AF	5,003,987		Grinwald	04/02/1991	
	AG	5,098,389		Сарриссі	03/24/1992	
	AH	5,156,591		Gross et al.	10/20/1992	
	AI	5,250,023		Lee et al.	10/05/1993	
	AJ	5,279,544		Gross et al.	Gross et al. 01/18/1994	
	AK	5,417,662		Hjertman et al.	05/23/1995	
	AL	5,527,288		Gross et al.	06/18/1996	
1	AM	5,591,139		Lin et al.	01/07/1997	
1	AN	5,801,057		Smart et al.	09/01/1998	
	AO	5,820,622		Gross et al.	10/13/1998	
	AP	5,848,991		Gross et al.	12/15/1998	
	AQ	5,876,582		Frazier 03/02/1999		
	AR	5,879,326		Godshall et al. 03/09/1999		
	AS	5,928,207		Pisano et al. 07/27/1999		
	AT	5,957,895		Sage et al. 09/28/1999		
	AU	5,997,501		Gross et al. 12/07/1999		
	ΑV	6,099,504		Gross et al.	08/08/2000	
	AW	6,334,856	Bl	Allen et al.	01/01/2002	
MW.	AX	6,346,095	BI	Gross et al.	02/12/2002	

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document			Name of Patentee	Date of Publication of	Pages, Columns, Lines,	
		Office ³	Number ⁴	Kind Code ⁵ (if known)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T ₆
	AY	CA	2 349 431		Canada	05/25/2000		
	AZ	EP	1 086 718	Al	Europe	03/28/2001		
	BA	EP	1 086 719	A1	Europe	03/28/2001		
	BB	EP	1 088 642	Al	Europe	04/04/2001		
	BC	EP	1 092 444	Al	Europe	04/18/2001		
	BD	wo	96/17648		PCT	06/13/1996		
	BE	wo	96/37155		PCT	11/28/1996		
	BF	wo	96/37256		PCT	11/28/1996		
	BG	wo	99/43350		PCT	09/02/1999		
	ВН	wo	99/64580		PCT	12/16/1999		
	Bi	wo	00/67647		PCT	11/16/2000		
	BJ	wo	00/74763	A2	PCT	12/14/2000		
	BK	wo	02/11669	A2	PCT	02/14/2002		

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1993 to passons are selected to respond to a collection of information unless it contains a valid CMB control number

Substitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 2

Complete if Known					
Application Number	10/028,989				
Filing Date	December 28, 2001				
First Named Inventor	PETTIS et al. MCCCI				
Group Art Unit	3763				
Examiner Name	Not Yet Assigned 2 4 2000				
Attorney Docket Number	7767-177469CHALD.				

	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
	BL	E. AUTRET et al., Therapie 1991, 46: 5-8.				
	ВМ	BRESSOLLE et al., "A Weibull Distribution Model for Intradermal Administration of Ceftazidime", Journal of Pharmaceutical Sciences, Vol. 82, No. 11, November 1993, pps. 1175-1178.				
	BN	HENRY et al., "Microfabricated Microneedles: A Novel Approach to Transdermal Drug Delivery", Journal of Pharmaceutical Sciences, Vol. 87, No. 8, August 1998, pps. 922-925.				
	ВО	KAUSHIK et al., "Transdermal Protein Delivery Using Microfabricated Microneedles", Oct/Nov 1999 (1 page).				
	BP	BURKOTH et al., "Transdermal and Transmucosal Powered Drug Delivery", Critical Review™ in Therapeutic Drug Carrier Systems, 16 (4), (1999), pps. 331-384.	-			
	BQ	MCALLISTER et al., "Three-Dimensional Hollow Microneedle and Microtube Arrays", Conference: Solid-State Sensors and Actuators Transducers-Conference, 1999; 10th; Vol. 12, pp 1098-1103.				

Examiner Signature	Carlaine S. William	Date Considered	1/12	204

SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

VENABLE

EXAMINER: Initial if reference considered, whether or not citation is In conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.